← All trials
NCT05179499
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2022
- Primary completion
- Jul 1, 2023
- Completion date
- Jul 30, 2025
- First posted
- Jan 5, 2022
- Last posted
- Feb 2, 2022
- Enrollment
- 3286
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of GlasgowLead sponsor
- University of LondonCollaborator
- University of EdinburghCollaborator
- University of GlasgowCollaborator
- Imperial College LondonCollaborator
- Northern Care Alliance NHS Foundation TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.